212 related articles for article (PubMed ID: 33766814)
1. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Duska LR; Filiaci VL; Walker JL; Holman LL; Hill EK; Moore RG; Ring KL; Pearl ML; Muller CY; Kushnir CL; Lankes HA; Samuelson MI; Carrick KS; Rajan A; Rodgers WH; Kohn EC; Piekarz R; Leslie KK
Clin Cancer Res; 2021 May; 27(10):2734-2741. PubMed ID: 33766814
[TBL] [Abstract][Full Text] [Related]
2. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
3. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
[TBL] [Abstract][Full Text] [Related]
4. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
5. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
8. Treatment for complex atypical hyperplasia of the endometrium.
Jobo T; Kawaguchi M; Imai M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(5):365-8. PubMed ID: 11766742
[TBL] [Abstract][Full Text] [Related]
9. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
[TBL] [Abstract][Full Text] [Related]
10. [Hormonal therapy for endometrial adenocarcinoma].
Susumu N; Aoki D; Suzuki N; Nozawa S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB;
Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130
[TBL] [Abstract][Full Text] [Related]
13. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
Emarh M
Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
[TBL] [Abstract][Full Text] [Related]
14. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
Kloke O; Klaassen U; Oberhoff C; Hartwich G; Szanto J; Wolf E; Heckmann M; Huhn R; Stephan L; Schnepper U; Donsbach GM; Bechtel C; Rudolph R; Berke A; Borquez D; Hawig I; Hirche H; Schindler AE; Seeber S; Becher R
Breast Cancer Res Treat; 1999 May; 55(1):51-9. PubMed ID: 10472779
[TBL] [Abstract][Full Text] [Related]
16. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system.
Abe O; Asaishi K; Izuo M; Enomoto K; Koyama H; Tominaga T; Nomura Y; Ohshima A; Aoki N; Tsukada T
Surg Today; 1995; 25(8):701-10. PubMed ID: 8520164
[TBL] [Abstract][Full Text] [Related]
17. Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Kanao H; Kato K; Utsugi K; Takeshima N
Jpn J Clin Oncol; 2018 Mar; 48(3):255-258. PubMed ID: 29351618
[TBL] [Abstract][Full Text] [Related]
18. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
19. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
Kim MK; Yoon BS; Park H; Seong SJ; Chung HH; Kim JW; Kang SB
Int J Gynecol Cancer; 2011 May; 21(4):673-7. PubMed ID: 21546871
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial.
von Minckwitz G; Loibl S; Brunnert K; Kreienberg R; Melchert F; Mösch R; Neises M; Schermann J; Seufert R; Stiglmayer R; Stosiek U; Kaufmann M
Eur J Cancer; 2002 Nov; 38(17):2265-71. PubMed ID: 12441263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
